Is it too late to buy Open Orphan shares?

Open Orphan’s shares are up over 100% in the past six months. Is there no stopping this specialist pharmaceutical firm?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Six months ago, Open Orphan’s (LSE: ORPH) shares hit a low of 13.5p. Fast-forward to February 19th, 2021, the shares hit a high of 32.90p. Could the rapid share price acceleration be attributable to Open Orphan’s knack of winning new contracts?

On March 9th, Open Orphan further grabbed my attention (and I thought of the company as a possible contender for my SIPP) when its subsidiary Venn Life Science secured a contract with Oxford BioTherapeutics in order to advance a breast cancer trial study.  

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Open Orphan seemed to be a on a roll in winning new business and, for diversification purposes, adding some pharma to my portfolio would be beneficial in the long term.

The firm said the contract was for a phase 1, open-label dose finding study, which would assess the safety, tolerability, pharmacokinetics and preliminary efficacy of ‘OBT076’, a CD205-directed antibody-drug conjugate, in recurrent and metastatic CD205-positive solid tumours and in women with CD205-positive HER2-negative metastatic breast cancer.

The breast cancer trial, if successful, could play a role in beating the fourth most common cause of cancer death in the UK, according to charity Cancer Research.

Open Orphan’s executive chairman Cathal Friel said: “This deal further demonstrates Open Orphan’s ability to execute on its significant pipeline of contracts with important pharmaceutical businesses.”

Expanding market

Over the past six months, the market for vaccine development and testing has grown rapidly, largely due to the outbreak of Covid-19. There is no doubt that this factor has benefited Open Orphan’s shares, and perhaps one of the reasons why the AIM-traded firm’s market capitalisation is growing – currently standing at £192m.

Open Orphan believes that governments and international pharmaceutical companies are making ‘catch-up’ investments in all types of vaccine development to ensure the effects of any global pandemic can be mitigated in the future. This will have a knock-on effect for Open Orphan’s hVIVO facility, the firm’s other commercial specialist service business.

Winning new contracts, an expanding vaccine development market and world class facilities – Open Orphan has Europe’s only 24-bedroom quarantine clinic with onsite virology – all make Open Orphan’s shares an attractive buy for me.

But what are the negatives? There are a few.

The pandemic has created a new type of “gold rush” in Covid-19 pharmaceutical and biotech shares, which might inevitably come to an end. Open Orphan shares could be the victim of hype and over-valuation, and there is a possible danger of buying this share at the top.

Back in October 2020, Open Orphan’s own brokers downplayed the prospects for the company’s share price despite securing a £10m Covid-19 challenge contract with the government. Arden Partners issued a buy rating on the stock with a target price of 32p, and joint broker finnCap also appeared to be backing a conservative outlook indicating a target price of 28p, with the shares trading around 29p today.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Sabuhi Gard has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

How I’d apply the Warren Buffett method to buying shares

Learning from billionaire investor Warren Buffett, our writer explains his own approach to investing in shares for his portfolio.

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

This dividend share yields under 1% — but I’d still buy it

This dividend share has a low yield. So why would our writer consider adding it to his income portfolio?

Read more »

Young lady working from home office during coronavirus pandemic.
Investing Articles

Looking for a good share to buy? Here’s how I do it

Here are two approaches our writer uses when hunting for a good share to buy for his portfolio to aim…

Read more »

man in shirt using computer and smiling while working in the office
Investing Articles

One cheap FTSE 100 share I’d buy for a new bull market

This FTSE 100 share is unloved and starting to look seriously cheap, says Roland Head.

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

How I’d invest £500 in UK shares in 2022

Investing a small amount of capital in UK shares can result in high commission costs. Zaven Boyrazian explains how to…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

2 battered FTSE dividend stocks to buy in July!

I'm still searching the FTSE 100 for the best bargains to buy. I think these two big dividend shares are…

Read more »

Woman pulling baffled face
Investing Articles

Can I trust Lloyds’ 6.1% dividend yield?

The Lloyds' share price has sunk in 2022, causing the bank's dividend yield to leap. But can I really trust…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

3 top stocks to buy before the market rebounds

Edward Sheldon highlights three beaten-up stocks he'd buy before global stock markets stage a recovery from their 2022 declines.

Read more »